<div data-page-id="doxcnHki1do5MlOGKQwe8VVwiyf" data-docx-has-block-data="true"> <div class="image-uploaded gallery old-record-id-doxcn8yamgak6AGswamUIsYQxPf" style="text-align: justify;" data-type="image" data-ace-gallery-json="{&quot;items&quot;:[{&quot;uuid&quot;:&quot;edf80688-91a6-465f-8c8c-fbbb7c946527&quot;,&quot;height&quot;:666,&quot;width&quot;:1000,&quot;currHeight&quot;:666,&quot;currWidth&quot;:1000,&quot;natrualHeight&quot;:666,&quot;natrualWidth&quot;:1000,&quot;pluginName&quot;:&quot;imageUpload&quot;,&quot;scale&quot;:1,&quot;src&quot;:&quot;https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2FboxcnnIfcqw3o0mBIkNL1rw9ZVc%2F%3Fmount_node_token%3Ddoxcn8yamgak6AGswamUIsYQxPf%26mount_point%3Ddocx_image&quot;,&quot;file_token&quot;:&quot;boxcnnIfcqw3o0mBIkNL1rw9ZVc&quot;,&quot;image_type&quot;:&quot;image/png&quot;,&quot;size&quot;:696992,&quot;comments&quot;:[]}]}"><span class="p"><img src="https://info.compassedu.hk/sucai/content/1659949052625/1659949052625.png" width="808" height="538" /></span></div> <div class="ace-line ace-line old-record-id-doxcnwwWMCsmWAYgiAJbckxrUEe" style="text-align: justify;">&nbsp;</div> <div class="ace-line ace-line old-record-id-doxcnwwWMCsmWAYgiAJbckxrUEe" style="text-align: justify;"><span class="p">由新加坡南洋理工大學(xué)李光前醫(yī)學(xué)院（LKCMedicine）領(lǐng)導(dǎo)的一組科學(xué)家在美國的一項(xiàng)重大研究計(jì)劃下贏得了200萬美元（280萬新元）的競爭性贈(zèng)款，用于開發(fā)可能引起大流行的病毒藥物，如SARS-CoV-2，登革熱和寨卡病毒。</span></div> <div class="ace-line ace-line old-record-id-doxcn4KeGCYw4Ca24wNmJcltRig" style="text-align: justify;"><span class="p">&nbsp;</span></div> <div class="ace-line ace-line old-record-id-doxcnC6ge2UMEOSyUwnpeKrYK5b" style="text-align: justify;"><span class="p">NTU團(tuán)隊(duì)進(jìn)行的研究是位于明尼蘇達(dá)大學(xué)的中西部抗病毒藥物發(fā)現(xiàn)（AViDD）大流行關(guān)注病原體中心努力的一部分，該中心在美國國家過敏和傳染病研究所（NIAID）的資助下開發(fā)抗病毒藥物。</span></div> <div class="ace-line ace-line old-record-id-doxcnsG0WAaMGqAIQ4ez86tfz5b" style="text-align: justify;"><span class="p">&nbsp;</span></div> <div class="ace-line ace-line old-record-id-doxcnWsE0GCQcUEMsBP4YNrlbGv" style="text-align: justify;"><span class="p">在NTU LKCMedicine的感染和免疫副教授以及教務(wù)長醫(yī)學(xué)主席Luo Dahai，結(jié)構(gòu)病毒學(xué)專家的帶領(lǐng)下，新加坡團(tuán)隊(duì)將利用NTU最先進(jìn)的分子和結(jié)構(gòu)生物學(xué)研究平臺和設(shè)施來確定新的抗病毒藥物靶點(diǎn)。研究團(tuán)隊(duì)中還有來自南洋理工大學(xué)結(jié)構(gòu)生物學(xué)研究所的Liew Chong Wai博士。</span></div> <div class="ace-line ace-line old-record-id-doxcnMQKC0ME2MM4Eg7CWzr0zbb" style="text-align: justify;"><span class="p">&nbsp;</span></div> <div class="ace-line ace-line old-record-id-doxcnWoEcCyCayEOg4sO8Xyk6yb" style="text-align: justify;"><span class="p">NTU團(tuán)隊(duì)將與著名科學(xué)家Reuben Harris教授領(lǐng)導(dǎo)的AViDD團(tuán)隊(duì)合作開發(fā)小分子候選藥物，旨在將最有前途的候選藥物帶到臨床研究階段。哈里斯教授是霍華德休斯醫(yī)學(xué)研究所的研究員，也是德克薩斯大學(xué)圣安東尼奧衛(wèi)生學(xué)院的教授和主席。</span></div> </div>